Wealth Enhancement Advisory Services LLC Has $3.62 Million Stake in Teleflex Incorporated $TFX

Key Points

• Wealth Enhancement Advisory Services LLC cut its Teleflex stake by 50% to 29,011 shares (about $3.62M), while other institutions—most notably Greenhaven Associates—opened a new ~$14.9M position; institutional ownership totals 95.62%.
• Teleflex badly missed quarterly expectations, reporting $1.93 EPS vs. $3.73 expected and $569M revenue vs. $912.6M expected (revenue down 28.5% YoY) and a negative net margin of 30.56%, though management guided FY2026 EPS to $6.25–$6.55.
• Analyst sentiment is mixed (3 Buys, 4 Holds, 2 Sells) with a consensus "Hold" and an average price target of $139; the stock has a $5.28B market cap and a 1.1% dividend yield.

Wealth Enhancement Advisory Services LLC lowered its holdings in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 50.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,011 shares of the medical technology company's stock after selling 29,036 shares during the period. Wealth Enhancement Advisory Services LLC owned about 0.07% of Teleflex worth $3,623,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Greenhaven Associates Inc. bought a new position in shares of Teleflex during the 4th quarter worth about $14,899,000. GAMMA Investing LLC raised its position in Teleflex by 240.5% in the fourth quarter. GAMMA Investing LLC now owns 1,338 shares of the medical technology company's stock worth $163,000 after purchasing an additional 945 shares in the last quarter. JPMorgan Chase & Co. raised its position in Teleflex by 41.5% in the third quarter. JPMorgan Chase & Co. now owns 123,343 shares of the medical technology company's stock worth $15,092,000 after purchasing an additional 36,178 shares in the last quarter. Allworth Financial LP lifted its stake in Teleflex by 451.9% during the third quarter. Allworth Financial LP now owns 1,490 shares of the medical technology company's stock worth $182,000 after purchasing an additional 1,220 shares during the period. Finally, Swiss Life Asset Management Ltd acquired a new stake in Teleflex during the third quarter valued at approximately $250,000. Institutional investors own 95.62% of the company's stock.

Wall Street Analyst Weigh In

TFX has been the subject of a number of recent research reports. Needham & Company LLC increased their target price on Teleflex from $138.00 to $147.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Weiss Ratings reiterated a "sell (d)" rating on shares of Teleflex in a research report on Friday. Raymond James Financial upgraded Teleflex from a "market perform" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Friday, March 27th. Wells Fargo & Company boosted their target price on shares of Teleflex from $116.00 to $130.00 and gave the company an "equal weight" rating in a research note on Friday, February 27th. Finally, Royal Bank Of Canada upped their target price on shares of Teleflex from $115.00 to $125.00 and gave the stock a "sector perform" rating in a report on Friday, February 27th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Teleflex currently has a consensus rating of "Hold" and an average price target of $139.00.

Teleflex Trading Up 4.0%

TFX stock opened at $119.54 on Wednesday. The business has a fifty day moving average price of $109.69 and a 200 day moving average price of $116.37. Teleflex Incorporated has a fifty-two week low of $100.18 and a fifty-two week high of $141.91. The stock has a market capitalization of $5.28 billion, a price-to-earnings ratio of -5.82, a P/E/G ratio of 0.72 and a beta of 0.87. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.54 and a quick ratio of 2.01.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 EPS for the quarter, missing analysts' consensus estimates of $3.73 by ($1.80). The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $912.57 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.Teleflex's revenue for the quarter was down 28.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.89 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Analysts expect that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, March 6th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex's dividend payout ratio is currently -6.62%.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.